Articles tagged with Breast Cancer
Researchers have identified a molecular switch driving the spread of aggressive triple-negative breast cancer, a subtype with poor outcomes. Restoring a naturally occurring molecule called miR-342 reduced metastatic disease in pre-clinical models.
Researchers developed a nanoplatform that addresses three barriers to TNBC immunotherapy by eliminating Tregs, destroying cancer cells, and activating innate immunity. In preclinical studies, the platform achieved 100% complete tumor regression and extended median survival beyond 70 days.
A telemedicine-supported home-injection model for patients with breast cancer has shown to reduce treatment burden by improving convenience and saving time. Most patients who completed home injections chose to continue this approach beyond the pilot, but barriers such as insurance denials and higher copayments may limit its broader imp...
A chemotherapy-free combination of targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option. The regimen produced durable responses while maintaining a manageable safety profile for many patients.
A nationwide claims data analysis in Japan found breast cancer survivors have a 1.57-fold higher risk of herpes zoster and a 1.70-fold higher risk of postherpetic neuralgia. Vaccination can reduce both the incidence of herpes zoster and the risk of complications, emphasizing the importance of prevention in breast cancer survivorship care.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers discovered a 'master switch' driving tumour growth in aggressive breast cancer and a targeted drug slowing tumour growth. The drug reduced cancer cell viability and tumour growth by 40-60% and extended survival in laboratory models.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Researchers developed a new 4D-printed breast cancer model that mimics the shape and movement of breast ducts. The study found that cancer cells behave differently when exposed to dynamic conditions, showing higher metabolic activity and greater survival after treatment with chemotherapy.
The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.
Researchers developed a method to predict how different types of breast cancer will respond to treatment using lab-grown mini tumors. The organoids mimicked a tumor's response to treatment and identified candidate combination therapies for cancers that don't respond to standard treatment.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A new study identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival in breast cancer patients. The interaction between these two genes changes dramatically depending on whether patients receive treatment, highlighting the importance of considering mol...
A randomized clinical trial found that digital patient-reported outcome (PRO) monitoring with alert-based interventions led to clinically meaningful reductions in fatigue and improved physical functioning in metastatic breast cancer patients. This study supports further evaluation of PRO monitoring in routine oncology care.
A digital treatment concept, PRO B, combines close monitoring via an app with on-demand in-person care to alleviate fatigue and improve daily life for patients with metastatic breast cancer. The approach has been shown to reduce exhaustion, improve physical functioning, and decrease hospital visits.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A new wearable electric-field device has been shown to slow the growth and spread of aggressive breast cancer in preclinical models. The technology uses low-intensity electric fields that interact with cancer cells in a controlled way, reducing tumor growth and increasing immune responses.
Researchers discovered how breast tumors recruit immune cells to attract nerves that support tumor growth and treatment resistance. Blocking nerve growth may boost the immune response to fight cancer.
New research reveals that NICE referral criteria for breast cancer risk assessment miss up to 95% of women under 50 who go on to develop the disease within 10 years. A full risk assessment tool, BOADICEA, identifies eight times more women in this age group at higher risk.
A phase 2 clinical trial found that combining two immunotherapies with standard chemotherapy prior to surgery improved pathologic complete response rates in high-risk, early-stage HER2-negative breast cancer patients. The regimen demonstrated strong activity among patients with ImPrint-positive tumors, including high pCR rates.
Combining cemiplimab, fianlimab, and paclitaxel-based neoadjuvant chemotherapy improved pathologic complete response rates in high-risk -negative breast cancer. Patients with the ImPrint immune signature showed enhanced sensitivity to the combination.
Research highlights importance of cardiovascular care in breast cancer patients and survivors throughout life. Cardiovascular risk factors and interventions are essential to prevent disease progression and improve quality of life.
The grant supports the development of therapies with fewer side effects for triple-negative breast cancer, a highly aggressive and difficult-to-treat form of breast cancer. The researchers aim to target UBR5 protein, which is overproduced in aggressive breast cancers and several other malignancies.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
A new study published in JAMA Network Open found an alarming rise in invasive breast cancer among Asian American women over the last two decades. Breast cancer rates are rising among nearly all ethnic groups much faster than any other U.S. group, with Chinese and Vietnamese women experiencing the highest increases.
A global analysis found alcohol use and smoking to be common risk factors for both breast cancer and atrial fibrillation/flutter in women ages 55 and older. High-risk zones were predominantly in Western countries with greater exposure to these lifestyle risks.
Scientists identified 81 previously unrecognized cancer-driving genes in basal-like breast cancer, a subset with poor outcomes. The discovery expands understanding of chromosomal rearrangements and opens possibilities for targeted therapy.
Breast cancers diagnosed during the first three years after childbirth are biologically more aggressive than similar cancers in women who have never given birth. The Oncotype DX Breast Recurrence Score suggests biological features associated with a higher risk of recurrence among these patients, including higher-grade tumors.
Researchers developed an AI test to predict breast cancer recurrence, which outperformed existing genomic tests in accuracy and speed. The multi-modal AI test uses pathology slides and clinical data to estimate the likelihood of return, offering a potential solution for faster and less costly predictions.
The US FDA has approved a new therapy regimen for patients with 'double-positive' metastatic breast cancer based on the PATINA study. The addition of palbociclib to standard therapy resulted in a more than 15-month improvement in progression-free survival.
Researchers classified breast cancer patients into three distinct subtypes based on the cancer-immunity cycle (CIC), predicting patient response to immunotherapy. The CIC score measures six key steps in the anti-tumor immune response, identifying new therapeutic targets and potential combination strategies.
A new portable ultrasound system enhances breast cancer detection with high-resolution, 3D images. The device requires no expertise to operate and can be used at home for early diagnosis and long-term monitoring.
The review discusses key AI concepts, including algorithms, models, architectures, machine learning, deep learning, and multimodal models. It highlights their clinical applications, such as detection of lymph node metastases, Nottingham grading, biomarker quantification, risk stratification, and prognostic prediction.
Researchers developed a compact, cost-effective diagnostic platform combining lensfree holography and deep learning for automated HER2 scoring. The system reached 84.9% accuracy for four-level HER2 classification and 94.8% accuracy for binary scoring, effectively lowering diagnostic risks.
Amelie G. Ramirez is studying the impact of therapeutic yoga on health-related quality of life, fatigue and physical function in Hispanic breast cancer survivors. She aims to find culturally responsive ways to support recovery through a comparison of standard physical therapy and therapeutic yoga.
Researchers found frequent silencing of TRAIL-R2 in breast tumors through promoter hypermethylation, associated with invasive ductal carcinoma and advanced tumor stage. Lower TRAIL-R2 expression was linked to more aggressive disease and reduced overall survival.
The FDA approved palbociclib in combination with trastuzumab and endocrine therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive advanced breast cancer. The PATINA trial demonstrated a significant prolongation of progression-free survival by over 15 months, providing new hope for individ...
Researchers used AI to analyze mammograms and found that women who developed breast cancer had increasing risk scores over time, while those who did not had stable scores. The study suggests that image-based AI risk scores can predict future breast cancer risk in women without a known genetic mutation or family history.
The collaboration aims to eliminate barriers to screening and access for medically underserved women, leveraging data science and community-based research to develop targeted solutions. By listening to residents' experiences and challenges, USC and Novartis will create lasting improvements in breast cancer care.
Scientists have discovered that fat tissue can be hijacked by tumor cells, leading to its spread throughout the body. The fat tissue releases adipomes, which deliver a 'lipid code' that reprograms cancer cells, boosting their growth and invasiveness.
A new study from Kaiser Permanente found that combining AI mammographic risk scores with polygenic and clinical risk scores more accurately identifies women at high risk of developing breast cancer than clinical risk scores used alone. The combined model was found to improve prediction accuracy, particularly among women at highest risk.
Researchers developed a method combining AI and mathematical models to accelerate MRI scans for breast cancer imaging, achieving improved tumor visibility and high diagnostic sensitivity. The ELITE method has the potential to improve not only MRI scans but also other imaging platforms.
Researchers have identified immune markers that can help doctors determine which breast cancer patients are unlikely to benefit from chemotherapy. The new AI-based method analyzes the body's own immune cells found near a tumor, providing additional insight to identify patients who can safely have chemotherapy withheld.
Researchers developed a metal-free carbon monoxide prodrug that significantly reduced metastatic tumor growth in pancreatic and triple-negative breast cancer models without signs of toxicity. The prodrug, CO-116, works by disrupting a signaling pathway that promotes cancer cell migration and metastasis.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A study published in Radiology found that three commercially available AI-based computer-assisted detection (AI-CAD) systems can identify early mammographic signs of breast cancer up to 6 years before diagnosis. This could help radiologists spot potential future cancers and allow for earlier intervention.
Researchers identified specific gene mutations and characteristics associated with early-onset breast cancer in young Black women. The study highlights the importance of genetic testing for this population, which faces lower screening rates than other groups.
Researchers found that DHED increased estrogen specifically in the brain of aged marmosets, leading to improved memory and sleep. The treatment also reversed neural changes caused by letrozole, a common breast cancer treatment. However, DHED had different effects on body temperature regulation in males and females.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
A retrospective analysis of over 110,000 women found that GLP-1 medication users were 30% less likely to develop breast cancer. The study suggests that GLP-1s may inhibit tumor growth and reduce systemic inflammation, which could play a role in breast cancer development.
Prediagnostic statin use showed no association with higher survival rates, but postdiagnostic use was linked to lower all-cause and breast cancer-specific mortality among hormone receptor-positive subtypes. Statin therapy may improve survival of these patient groups.
Researchers used an open-source AI model called Mirai to quickly identify high-risk patients and expedite their diagnostic process. This led to a significant reduction in wait times, with some women receiving biopsy results within days of having their mammograms done.
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
Adding fovinaciclib to first-line aromatase inhibitor therapy confers significant progression-free survival benefits and consistent improvements in efficacy outcomes. The treatment also has manageable safety profiles with no negative impact on quality of life.
The study found that population-based pathogenic variant testing reveals different subsets of high-risk women than clinical risk factors and polygenic risk scores. This highlights the importance of incorporating PV testing into risk-based screening for breast cancer.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers found that obesity alters the biological changes in breast cancer cells, enabling them to survive and thrive. The study's findings could improve prediction and treatment of invasive breast cancer, reducing overtreatment and unnecessary treatments.